Let us not forget that although the sp of EXEL has been inactive the company has not been in active in the last six months.
1. They raised over a $600 Million to fund all their needs for the next 2 years.
2. They received FDA approval to market cabozantinib for MTC.
3.They renamed cabozantinib with a really commercially viable name; Cometriq.
4. They are currently recruiting or are actively involved in 37 different trials which you can find at clinicaltrialsdotgov.
5.Began marketing Cometriq in the US and Europe (and although EXEL is not involved apparently it is also being marketed in China and India).
6.Announced that their jointly devloped GDC-0973 (with Genentech/Roche) has been advanced to a P-3 trial
for metastatic melanoma.
I think that, notwithstanding some disappointments in the share price, the company has been anything but inactive.